SCHEMBL29630239

SCHEMBL29630239

Cc1ncsc1COc1ccc2oc(C)c(C(=O)O)c2c1F

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 2/20 0.42
HTT P42858 2/20 0.42
SLC26A4 O43511 7/20 0.38
KMT2A Q03164 5/20 0.38
MEN1 O00255 4/20 0.38
BLM P54132 1/20 0.38
ATM Q13315 1/20 0.38
EGFR P00533 1/20 0.37
APEX1 P27695 1/20 0.37
CASP3 P42574 1/20 0.36
SENP8 Q96LD8 1/20 0.36
SENP7 Q9BQF6 1/20 0.36
SENP6 Q9GZR1 1/20 0.36
POLB P06746 1/20 0.36
FFAR4 Q5NUL3 1/20 0.34
KDM4E B2RXH2 2/20 0.33
PKM P14618 1/20 0.33
ANO1 Q5XXA6 2/20 0.32
MAPK1 P28482 1/20 0.32
L3MBTL1 Q9Y468 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24484900 1.00 LMNA (0.42) LMNAHTTSLC26A4KMT2AMEN1
SCHEMBL29095791 0.89 LMNA (0.43) LMNAHTTPOLBKDM4EMAPK1
SCHEMBL29630220 0.89 LMNA (0.43) LMNAHTTPOLBKDM4EMAPK1
SCHEMBL29630194 0.84 SLC26A4 (0.36) LMNAHTTSLC26A4KMT2AMEN1
SCHEMBL29095745 0.84 SLC26A4 (0.36) LMNAHTTSLC26A4KMT2AMEN1
SCHEMBL24484858 0.82 GABRA1 (0.32) LMNAHTT
SCHEMBL29629758 0.82 GABRA1 (0.32) LMNAHTT
SCHEMBL24484862 0.81
SCHEMBL29629942 0.81
SCHEMBL24484890 0.80 LMNA (0.44) LMNAHTTSLC26A4KMT2AMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12209081-B2 Heterocycle derivatives for treating TRPM3 mediated disorders KATHOLIEKE UNIVERSITEIT LEUVEN (BE) 2025-01-28 US disclosed
WO-2022112352-A1 HETEROCYCLE DERIVATIVES FOR TREATING TRPM3 MEDIATED DISORDERS KATHOLIEKE UNIVERSITEIT LEUVEN (BE) 2022-06-02 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12209081-B2 Heterocycle derivatives for treating TRPM3 mediated disorders TRPM4, TRPM6, TRPM2 LMNA 3056/4885HTT 1601/4885SLC26A4 628/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.